ストックスクリーナーアプリを入手
49.60
6.04%
-3.19
前日終値:
$52.79
開ける：
$52.56
24時間の取引高:
1.64M
Relative Volume:
0.79
時価総額：
$4.68B
収益：
$536.20M
当期純損益:
$-45.64M
株価収益率:
-92.74
EPS:
-0.5348
ネットキャッシュフロー:
$-28.94M
1週間 パフォーマンス:
-4.84%
1か月 パフォーマンス:
-21.87%
6か月 パフォーマンス:
+25.44%
1年 パフォーマンス:
+80.30%
1日の値動き範囲:
$49.46
$52.56
1週間の範囲:
$49.46
$55.57
52週間の値動き範囲:
$22.59
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
49.60 | 4.68B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Nigeria
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere CFO (NASDAQ: TVTX) sells 50K shares in pre-set trading plan - Stock Titan
Travere Therapeutics (TVTX) CEO trades 400K shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ: TVTX) officer plans 112,850-share sale after recent 96,198-share trade - Stock Titan
After $6M sale, Travere (NASDAQ: TVTX) insider plans another stock move - Stock Titan
Travere Therapeutics (TVTX) insider plans 172,717-share sale after option exercise - Stock Titan
Insider plans 39,576-share sale at Travere Therapeutics (NASDAQ: TVTX) in 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer may sell shares after cashing in options - Stock Titan
$2.9M planned stock sale at Travere (NASDAQ: TVTX) comes from equity awards - Stock Titan
Over 100,000 Travere (NASDAQ: TVTX) shares lined up for insider sale - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans Rule 144 sale of compensation shares - Stock Titan
TVTX Form 4 FilingsTravere Therapeutics, Inc. SEC Form 4 - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan
Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews
Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia
Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan
TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com UK
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 68.25 USD - investing.com
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com UK
Travere Therapeutics' Outlook Brightens As Turnaround Looms - Investor's Business Daily
FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari - Medical Marketing and Media
Seong Chi: Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies - Oncodaily
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting - Kalkine Media
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
Travere Therapeutics Inc (TVTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PETER HEERMA | Officer |
Sep 17 '26 |
Proposed Sale |
63.48 |
8,282 |
525,741 |
0 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Option Exercise |
23.34 |
108,493 |
2,532,227 |
541,379 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
22.40 |
8,282 |
185,517 |
125,348 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Sale |
64.61 |
108,493 |
7,009,671 |
432,886 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Sale |
65.07 |
8,282 |
538,917 |
117,066 |
| ERIC DUBE | Director |
Sep 17 '26 |
Proposed Sale |
63.48 |
108,493 |
6,887,136 |
0 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Option Exercise |
23.34 |
195,841 |
4,570,929 |
628,727 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 16 '26 |
Sale |
63.43 |
172,717 |
10,956,088 |
117,066 |
| ERIC DUBE | Director |
Sep 16 '26 |
Proposed Sale |
62.51 |
195,841 |
12,242,021 |
0 |
| ROTE WILLIAM E. | Chief Research Officer |
Sep 16 '26 |
Option Exercise |
21.29 |
112,850 |
2,402,186 |
211,047 |
9.95%
大文字化:
|
ボリューム (24 時間):